Cancer Control and Population Sciences Program ABSTRACT The mission of the Cancer Control and Population Sciences (CCPS) Program is to advance the science and application of cancer etiology, prevention, and outcomes research. The goal is to reduce the burden of cancer and its sequelae across all segments of the population through collaborative, multidisciplinary efforts. To achieve this goal, the Program has three themes: 1) To discover host and environmental factors contributing to cancer; 2) To identify factors to reduce health-related morbidity and mortality from cancer treatment; and 3) To develop, implement and evaluate interventions to reduce cancer-related morbidity/mortality and improve quality of life (QOL). Within each of these themes, research is on-going to reduce health disparities within our catchment area. As importantly, each theme encompasses strong education components ranging from K-12 programs in the community to healthcare provider and caregiver training for better communication and care for cancer survivors. Targeted recruits with national prominence add both depth and breadth to the Program and include Drs. Seewaldt, Chlebowski, Gray, Kittles, and Yee. The CCPS Program is particularly invested in the following key areas: building a robust portfolio of research in cancer etiology and biomarker development; strengthening the focus on understanding risk factors for treatment-related complications and developing tailored interventions to reduce morbidity in cancer survivors; recognizing causes of disparities in outcome unique to disease type and developing tailored interventions to systematically mitigate the disparities; and continuing to build upon the strong portfolio of research in psychosocial outcomes and tailored interventions to improve QOL. Sponsored activities include monthly work in progress meetings, monthly seminars, an annual retreat, and annual pilot funding. Membership: 23 Program Members representing 4 basic and clinical departments Publications: 410 total. 34.6% intra-programmatic; 20.2% inter-programmatic; 58.0% inter-institutional Funding: $7,770,700 peer-reviewed; $5,788,708 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849214
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512
Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528

Showing the most recent 10 out of 1396 publications